UBS receives national banking licence for the US

UBS has received a US national banking licence, allowing it to offer demand deposits and additional credit products and to expand its US lending and deposit business. Management says the licence supports growth, could broaden the client base beyond ultra-high-net-worth clients, and boost assets and profitability. The bank reported $14.1bn of net outflows in the Americas in Q4 2025 and about 200 fewer US advisors year-over-year; shares were down ~1% on the news.

Analysis

The licence gives UBS an explicit mechanical path to convert a slice of its US asset base into low-cost, FDIC-style deposits; even a conservative conversion of $30–60bn into core deposits would reduce funding costs versus wholesale alternatives by roughly 75–100bp, implying incremental NII of ~$225–600m annually and a near-term ROE boost of 20–50bp depending on capital treatment. This is not immediate — expect a 12–36 month runway as product rollout, systems integration and compliance scaling occur — but the economics are sticky once retail-style deposits are in place and drive structural margin improvement versus a pure wealth-fee model.

Competitive dynamics will shift subtly: mass affluent and upper-wealth segments become contestable to large private banks, pressuring fee schedules and cross-sell economics at incumbents (Morgan Stanley, Bank of America/Merrill). Second-order effects include lower reliance on repo and wholesale funding, reduced securities-lending/netted-funding volatility, and potential margin compression for third-party prime lenders that previously arbitraged funding differentials with UBS balance-sheet support.

Risks and catalysts to monitor: the path is vulnerable to regulatory conditions (capital / liquidity add-ons), advisor attrition trends, and initial product pricing missteps. Key near-term catalysts are quarterly Americas flows, advisor headcount stabilization, first announced US deposit products (6–12 months) and NII commentary; a regulatory hiccup or failure to win non-HNW deposits would reverse the thesis quickly and present binary downside within 3–6 months.

Key Decisions for Investors

• Long UBS (ticker: UBS) — buy on weakness or as staged entries: 33% position at present levels, add to 66% if shares fall 8–12% or on confirmation of first US deposit flow print. Timeframe 12–24 months; target +30% if UBS nets $30–60bn of core deposits lifting NII $225–600m; downside -35% on severe regulatory/flow reversal. Use 10–12% trailing stop-loss for tactical sizing.
• Pair trade: Long UBS / Short MS (Morgan Stanley) equal dollar notional — timeframe 12–36 months. Rationale: UBS gains funding-cost advantage while MS retains fee base but less upside from cheaper deposits; target spread capture ~15–25% relative outperformance for UBS. Stop if spread narrows by >10% absolute within 3 months.
• Options hedge/levered exposure: Buy a 12-month UBS call and sell a 6–8% OTM call to finance (call spread) — limits premium outlay while keeping upside participation to capture the rollout narrative. If you prefer downside protection instead, buy 9–12 month puts sized at 10–15% of position notional to cap regulatory tail risk; cost should be evaluated versus portfolio convexity needs.
• Event-monitoring alert: Establish small, liquid CDS or put protection exposure (if available) for regulatory-tail insurance sized to expected benefit from deposit conversion (i.e., protection sized to ~15–25% of equity position) and unwind on three consecutive quarters of positive US deposit inflow prints or clear regulatory guidance.